Skip to main content
Terug
ZVRA logo

Zevra Therapeutics, Inc.

Datakwaliteit: 100%
ZVRA
NASDAQ Healthcare Biotechnology
€ 9,16
▼ € 0,24 (-2,55%)
Marktkapitalisatie: 537,80M
Dagbereik
€ 9,15 € 9,48
52-Weeksbereik
€ 6,19 € 13,16
Volume
504.301
50D / 200D Gem.
€ 9,04 / € 9,48
Vorige Slotkoers
€ 9,40

Quick Summary

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (633 peers)

Metriek Aandeel Sector Mediaan
P/E 6,5 0,2
P/B 3,5 2,8
ROE % 85,7 3,7
Net Margin % 78,2 3,9
Rev Growth 5Y % 38,8 9,7
D/E 0,4 0,2

Koersdoel Analisten

Hold
€ 24,25 +164.7%
Low: € 23,00 High: € 26,00
Forward K/W
18,76
Forward WPA
€ 0,49
WPA Groei (sch.)
+0,0%
Omzet Sch.
143,28M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 3,42
€ 3,00 – € 4,42
 406,55M 5
FY2029 € 3,04
€ 2,67 – € 3,94
 361,42M 2
FY2028 € 2,51
€ 1,60 – € 4,36
 306,96M 7

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-03-09 € 0,05 € 0,21 +321,4%
2025-11-05 -€ 0,02 -€ 0,01 +50,0%
2025-08-12 € 2,19 € 1,21 -44,7%
2025-05-13 -€ 0,21 -€ 0,06 +71,4%
2025-03-11 -€ 0,39 -€ 0,67 -71,8%
2024-11-12 -€ 0,44 -€ 0,69 -56,8%
2024-08-13 -€ 0,47 -€ 0,48 -2,1%
2024-05-08 -€ 0,49 -€ 0,40 +18,4%

Dividend History

Yield

0,00%

Payout Ratio

0,00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Belangrijkste Punten

Revenue grew 38,84% annually over 5 years — strong growth
ROE of 85,66% indicates high profitability
Net margin of 78,17% shows strong profitability
Debt/Equity of 0,41 — conservative balance sheet
Negative free cash flow of -2,43M
P/E of 6,46 — trading at a low valuation

Groei

Revenue Growth (5Y)
38,84%
Revenue (1Y)350,91%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
85,66%
ROIC-1,46%
Net Margin78,17%
Op. Margin-3,98%

Veiligheid

Debt / Equity
0,41
Current Ratio5,68
Interest Coverage-0,53

Waardering

P/E Ratio
6,46
Forward P/E18,76
P/B Ratio3,48
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 350,91% Revenue Growth (3Y) 96,90%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 38,84% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 106,47M Net Income (TTM) 83,23M
ROE 85,66% ROA 29,23%
Gross Margin 84,52% Operating Margin -3,98%
Net Margin 78,17% Free Cash Flow (TTM) -2,43M
ROIC -1,46% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,41 Current Ratio 5,68
Interest Coverage -0,53
Dividends
Dividend Yield 0,00% Payout Ratio 0,00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 6,46 Forward P/E 18,76
P/B Ratio 3,48 P/S Ratio 5,05
PEG Ratio -0,04 Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 3,75 Fwd Earnings Yield 5,33%
FCF Yield -0,45%
Market Cap 537,80M Enterprise Value 538,60M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 106,47M 23,61M 27,46M 10,16M 28,65M
Net Income 83,23M -105,51M -46,05M -26,77M -8,56M
EPS (Diluted) 1,35 -2,28 -1,30 -0,78 -2,11
Gross Profit 89,99M 16,20M 24,52M 9,94M 26,59M
Operating Income -4,23M -87,00M -49,60M -42,57M 7,73M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 284,73M 178,13M 172,33M 115,34M 132,94M
Total Liabilities 130,07M 138,46M 110,46M 40,22M 5,82M
Shareholders' Equity 154,66M 39,67M 61,86M 75,12M 127,12M
Total Debt 63,21M 60,30M 43,77M 18,78M 1,61M
Cash & Equivalents 62,41M 33,79M 43,05M 65,47M 112,35M
Current Assets 223,01M 86,03M 86,94M 92,83M 115,06M
Current Liabilities 39,28M 34,07M 73,72M 12,02M 4,23M

Strategiescores

This stock passed the criteria for 0 strategies

Score = fit strength (0–100)
Rank = position among all matches

Recente Activiteit

Uitgestapt Contrarian Investing (David Dreman)
Mar 26, 2026
Ingestapt Contrarian Investing (David Dreman)
Mar 24, 2026